UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________
FORM 8-K
______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 2, 2022
______________________________
(Exact name of registrant as specified in its charter)
______________________________
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) | |||||||||||||||
(Address of principal executive offices, including zip code)
(801 ) 432-9000
(Registrant's telephone number)
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 2, 2022, the Company issued a press release announcing its financial results for the three months ended September 30, 2022. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference.
The information furnished in this Item 2.02 and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | ||||||||||
| 99.1 | |||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: | November 2, 2022 | By: | LIFEVANTAGE CORPORATION /s/ Carl A. Aure | |||||||||||
| Name: | Carl A. Aure | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
LifeVantage Announces Financial Results for the
First Quarter of Fiscal 2023
Salt Lake City, UT, November 2, 2022, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its first fiscal quarter ended September 30, 2022.
First Quarter Fiscal 2023 Summary*:
•Revenue of $51.8 million, a decrease of 2.7% from the prior year period. Excluding the negative impact of foreign currency fluctuations, first quarter revenue was up approximately 2.3%;
•Revenue in the Americas decreased 0.2%. Revenue in the United States increased 1.1%. Revenue in Asia/Pacific & Europe decreased 8.2%. Excluding the negative impact of foreign currency fluctuations, first quarter revenue in Asia/Pacific & Europe increased approximately 7.4%;
•Total active accounts declined 6.7% from the prior year period to 153,000, reflecting a decline of 7.8% in the Americas and a 4.1% decline in Asia/Pacific & Europe;
•Net income per diluted share were $0.05, versus $0.25 per diluted share a year ago;
•Adjusted earnings per diluted share were $0.06, versus $0.23 a year ago;
•Adjusted EBITDA of $2.8 million, compared to $5.8 million a year ago; and
•Strong balance sheet with $17.6 million of cash and no debt.
* All comparisons are on a year over year basis and compare the first quarter of fiscal 2023 to the first quarter of fiscal 2022, unless otherwise noted.
“Results in the first quarter demonstrated continued momentum across our strategic initiatives around innovation and engagement,” said Steve Fife, President and Chief Executive Officer of LifeVantage. “The number of active independent distributors was up 1.6% on a year-over-year basis driven by an 18% increase in Asia/Pacific & Europe and revenue versus the prior year period was up 2.3% on a constant currency basis. Sales of the new Collagen product we launched in June far exceeded our initial expectations and the recent expansion of our flagship product Protandim NAD to Japan, Australia and New Zealand should help to propel growth in these key markets. At our global convention in October, energy levels remained very high and sharper messaging around our core focus on optimizing health and evolving possibilities continues to resonate well with distributors. Profitability is also poised to improve as we recently implemented a price increase that will serve to alleviate margin pressures stemming from inflationary factors. While the macroeconomic environment remains challenging, we are off to a solid start in fiscal 2023, making steady progress on transforming LifeVantage into a more dynamic, customer-centric organization that delivers consistent, sustainable growth and increases value for shareholders.”
First Quarter Fiscal 2023 Results
For the first fiscal quarter ended September 30, 2022, the Company reported revenue of $51.8 million, a 2.7% decrease over the first quarter of fiscal 2022. Excluding the negative impact of foreign currency fluctuations, first quarter revenue was up 2.3%. Revenue in the Americas region for the first quarter of fiscal 2023 decreased 0.2%, which includes a 1.1% increase in the United States. Revenue in the Asia/Pacific & Europe region decreased 8.2% compared to the prior year period. On a constant currency basis, revenue in Asia/Pacific & Europe increased 7.4% for the three months ended September 30, 2022 as compared to the prior year period.
Gross profit for the first quarter of fiscal 2023 was $41.8 million, or 80.8% of revenue, compared to $43.8 million, or 82.3% of revenue, for the same period in fiscal 2022. The decline in gross profit margin was primarily driven by elevated shipping expenses and other inflationary factors, as well as shifts in geographic and product sales mix.
Commissions and incentives expense for the first quarter of fiscal 2023 was $23.8 million, or 46.0% of revenue, compared to $24.1 million, or 45.3% of revenue, for the same period in fiscal 2022. The increase in commissions
and incentives expense as a percentage of revenue is due mainly to the timing and magnitude of various promotional and incentive programs.
Selling, general and administrative (SG&A) expense for the first quarter of fiscal 2023 was $16.7 million, or 32.3% of revenue, compared to $15.1 million, or 28.3% of revenue, for the same period in fiscal 2022. Adjusted for nonrecurring expenses, which are detailed in the GAAP to non-GAAP reconciliation tables included at the end of this press release, adjusted non-GAAP SG&A expenses for the first quarter of fiscal 2023 were $16.6 million, or 32.1% of revenue, compared to adjusted non-GAAP SG&A expenses for the first quarter of fiscal 2022 of $15.3 million, or 28.8% of revenue. The increase in adjusted non-GAAP SG&A expense was primarily attributable to increased event related costs and travel expenses as restrictions related to the COVID-19 pandemic have begun to subside outside of the US market, as well as increased expenses associated with legal fees, endorsement agreements, product testing and personnel compared to the prior year period.
Operating income for the first quarter of fiscal 2023 was $1.3 million compared to $4.6 million for the first quarter of fiscal 2022. Accounting for non-GAAP adjustments noted previously, adjusted non-GAAP operating income for the first quarter of fiscal 2023 was $1.4 million compared to $4.4 million for the first quarter of fiscal 2022.
Net income for the first quarter of fiscal 2023 was $0.6 million, or $0.05 per diluted share, which compares to net income of $3.3 million, or $0.25 per diluted share for the first quarter of fiscal 2022. Accounting for non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for the first quarter of fiscal 2023 was $0.7 million, or $0.06 per diluted share, compared to $3.1 million, or $0.23 per diluted share for the first quarter of fiscal 2022.
Adjusted EBITDA was $2.8 million for the first quarter of fiscal 2023, versus $5.8 million for the comparable period in fiscal 2022.
Balance Sheet & Liquidity
The Company used $1.3 million of cash from operations during the first three months of fiscal 2023 compared to generating $0.5 million in the same period in fiscal 2022. Cash and cash equivalents at September 30, 2022 were $17.6 million, compared to $20.2 million at June 30, 2022, and there was no debt outstanding.
Dividend Announcement
Today the Company announced the declaration of a cash dividend of $0.03 per common share. The dividend will be paid on December 15, 2022 to all stockholders of record at the close of business on December 1, 2022.
Fiscal Year 2023 Guidance
The Company continues to expect to generate revenue in the range of $200 million to $212 million in fiscal year 2023 and adjusted EBITDA of $12 million to $14 million, with adjusted earnings per share in the range of $0.27 to $0.39, which assumes a full year tax rate of approximately 26%. This guidance reflects the current trends in the business. The Company's guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share excludes any non-operating or non-recurring expenses that may materialize during fiscal 2023. The Company is not providing guidance for GAAP earnings per diluted share for fiscal 2023 due to the potential occurrence of one or more non-operating, one-time expenses, which the Company does not believe it can reliably predict.
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (855) 327-6837 from the U.S. International callers can dial (631) 891-4304. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, November 9, 2022, by dialing (844) 512-2921 from the U.S. and entering confirmation code 10020245, or (412) 317-6671 from international locations, and entering confirmation code 10020245.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at http://investor.lifevantage.com/events-and-presentations or directly at https://viavid.webcasts.com/starthere.jsp?ei=1570196&tp_key=df30a03ea7.The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. The Company’s line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+™, ProBio™, IC Bright®, and Daily Wellness™ dietary supplements, the TrueScience® line of skin, hair, bath & body, and targeted relief products. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs, Axio® its nootropic energy drink mixes, and PhysIQ™, its smart weight management system. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.
Cautionary Note Regarding Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, the impact of COVID-19 on our business, expected financial performance, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments as a result of future COVID-19 developments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this
data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.
Investor Relations Contacts:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||
| CONSOLIDATED BALANCE SHEETS | |||||||||||
| (Unaudited) | |||||||||||
| (In thousands, except per share data) | September 30, 2022 | June 30, 2022 | |||||||||
| ASSETS | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ | 17,619 | $ | 20,190 | |||||||
| Accounts receivable | 1,916 | 3,338 | |||||||||
| Income tax receivable | — | 1,752 | |||||||||
| Inventory, net | 18,636 | 16,472 | |||||||||
| Prepaid expenses and other | 4,752 | 5,205 | |||||||||
| Total current assets | 42,923 | 46,957 | |||||||||
| Property and equipment, net | 9,403 | 9,500 | |||||||||
| Right-of-use assets | 10,410 | 11,040 | |||||||||
| Intangible assets, net | 554 | 587 | |||||||||
| Deferred income tax asset | 3,044 | 1,289 | |||||||||
| Other long-term assets | 1,266 | 1,333 | |||||||||
| TOTAL ASSETS | $ | 67,600 | $ | 70,706 | |||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable | $ | 7,846 | $ | 7,462 | |||||||
| Commissions payable | 7,367 | 7,285 | |||||||||
| Income tax payable | 107 | 453 | |||||||||
| Lease liabilities | 2,397 | 2,601 | |||||||||
| Other accrued expenses | 5,052 | 7,927 | |||||||||
| Total current liabilities | 22,769 | 25,728 | |||||||||
| Long-term lease liabilities | 12,642 | 13,154 | |||||||||
| Other long-term liabilities | 299 | 308 | |||||||||
| Total liabilities | 35,710 | 39,190 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders' equity | |||||||||||
| Preferred stock — par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding | — | — | |||||||||
| Common stock — par value $0.0001 per share, 40,000 shares authorized and 12,560 and 12,493 issued and outstanding as of September 30, 2022 and June 30, 2022, respectively | 1 | 1 | |||||||||
| Additional paid-in capital | 131,726 | 131,075 | |||||||||
| Accumulated deficit | (98,204) | (98,437) | |||||||||
| Accumulated other comprehensive loss | (1,633) | (1,123) | |||||||||
| Total stockholders’ equity | 31,890 | 31,516 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 67,600 | $ | 70,706 | |||||||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||
| (Unaudited) | |||||||||||
| Three Months Ended September 30, | |||||||||||
| (In thousands, except per share data) | 2022 | 2021 | |||||||||
| Revenue, net | $ | 51,774 | $ | 53,224 | |||||||
| Cost of sales | 9,942 | 9,431 | |||||||||
| Gross profit | 41,832 | 43,793 | |||||||||
| Operating expenses: | |||||||||||
| Commissions and incentives | 23,813 | 24,105 | |||||||||
| Selling, general and administrative | 16,729 | 15,076 | |||||||||
| Total operating expenses | 40,542 | 39,181 | |||||||||
| Operating income | 1,290 | 4,612 | |||||||||
| Other expense: | |||||||||||
| Interest expense, net | — | (3) | |||||||||
| Other expense, net | (438) | (177) | |||||||||
| Total other expense | (438) | (180) | |||||||||
| Income before income taxes | 852 | 4,432 | |||||||||
| Income tax expense | (242) | (1,116) | |||||||||
| Net income | $ | 610 | $ | 3,316 | |||||||
| Net income per share: | |||||||||||
| Basic | $ | 0.05 | $ | 0.25 | |||||||
| Diluted | $ | 0.05 | $ | 0.25 | |||||||
| Weighted-average shares outstanding: | |||||||||||
| Basic | 12,457 | 13,394 | |||||||||
| Diluted | 12,495 | 13,469 | |||||||||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||||||||||||||||||||||||||
| Revenue by Region | |||||||||||||||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||||||||||||||
| Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
| (In thousands) | 2022 | 2021 | |||||||||||||||||||||||||||||||||
| Americas | $ | 36,369 | 70 | % | $ | 36,449 | 68 | % | |||||||||||||||||||||||||||
| Asia/Pacific & Europe | 15,405 | 30 | % | 16,775 | 32 | % | |||||||||||||||||||||||||||||
| Total | $ | 51,774 | 100 | % | $ | 53,224 | 100 | % | |||||||||||||||||||||||||||
| Active Accounts | |||||||||||||||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||||||||||||||
| As of September 30, | |||||||||||||||||||||||||||||||||||
| 2022 | 2021 | Change from Prior Year | Percent Change | ||||||||||||||||||||||||||||||||
Active Independent Distributors (1) | |||||||||||||||||||||||||||||||||||
| Americas | 37,000 | 59 | % | 40,000 | 65 | % | (3,000) | (7.5) | % | ||||||||||||||||||||||||||
| Asia/Pacific & Europe | 26,000 | 41 | % | 22,000 | 35 | % | 4,000 | 18 | % | ||||||||||||||||||||||||||
| Total Active Independent Distributors | 63,000 | 100 | % | 62,000 | 100 | % | 1,000 | 1.6 | % | ||||||||||||||||||||||||||
Active Customers (2) | |||||||||||||||||||||||||||||||||||
| Americas | 69,000 | 77 | % | 75,000 | 74 | % | (6,000) | (8.0) | % | ||||||||||||||||||||||||||
| Asia/Pacific & Europe | 21,000 | 23 | % | 27,000 | 26 | % | (6,000) | (22.2) | % | ||||||||||||||||||||||||||
| Total Active Customers | 90,000 | 100 | % | 102,000 | 100 | % | (12,000) | (11.8) | % | ||||||||||||||||||||||||||
Active Accounts (3) | |||||||||||||||||||||||||||||||||||
| Americas | 106,000 | 69 | % | 115,000 | 70 | % | (9,000) | (7.8) | % | ||||||||||||||||||||||||||
| Asia/Pacific & Europe | 47,000 | 31 | % | 49,000 | 30 | % | (2,000) | (4.1) | % | ||||||||||||||||||||||||||
| Total Active Accounts | 153,000 | 100 | % | 164,000 | 100 | % | (11,000) | (6.7) | % | ||||||||||||||||||||||||||
| (1) Active Independent Distributors have purchased product in the prior three months for retail or personal consumption. | |||||||||||||||||||||||||||||||||||
| (2) Active Customers have purchased product in the prior three months for personal consumption only. | |||||||||||||||||||||||||||||||||||
| (3) Total Active Accounts is the sum of Active Independent Distributor accounts and Active Customer accounts. | |||||||||||||||||||||||||||||||||||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||
| Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA | |||||||||||
| (Unaudited) | |||||||||||
| Three Months Ended September 30, | |||||||||||
| (In thousands) | 2022 | 2021 | |||||||||
| GAAP Net income | $ | 610 | $ | 3,316 | |||||||
| Interest Expense | — | 3 | |||||||||
| Provision for income taxes | 242 | 1,116 | |||||||||
| Depreciation and amortization | 841 | 793 | |||||||||
| Non-GAAP EBITDA: | 1,693 | 5,228 | |||||||||
| Adjustments: | |||||||||||
| Stock compensation expense | 602 | 645 | |||||||||
| Other expense, net | 438 | 177 | |||||||||
Other adjustments(1) | 89 | (249) | |||||||||
| Total adjustments | 1,129 | 573 | |||||||||
| Non-GAAP Adjusted EBITDA | $ | 2,822 | $ | 5,801 | |||||||
| (1) Other adjustments breakout: | |||||||||||
| Class-action lawsuit expenses, net of recoveries | 89 | (249) | |||||||||
| Total adjustments | $ | 89 | $ | (249) | |||||||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||
| Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS | |||||||||||
| (Unaudited) | |||||||||||
| Three Months Ended September 30, | |||||||||||
| (In thousands) | 2022 | 2021 | |||||||||
| GAAP Net income | $ | 610 | $ | 3,316 | |||||||
| Adjustments: | |||||||||||
| Class-action lawsuit expenses, net of recoveries | 89 | (249) | |||||||||
Tax impact of adjustments(1) | (2) | 63 | |||||||||
| Total adjustments, net of tax | 87 | (186) | |||||||||
| Non-GAAP Net Income: | $ | 697 | $ | 3,130 | |||||||
| Three Months Ended September 30, | |||||||||||
| 2022 | 2021 | ||||||||||
| Diluted earnings per share, as reported | $ | 0.05 | $ | 0.25 | |||||||
| Total adjustments, net of tax | 0.01 | (0.01) | |||||||||
Non-GAAP adjusted diluted earnings per share(2) | $ | 0.06 | $ | 0.23 | |||||||
| (1) Tax impact is based on the estimated annual tax rate for the years ended June 30, 2023 and 2022, respectively | |||||||||||
| (2) May not add due to rounding. | |||||||||||